Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsBrian Lian ...
1don MSN
Wall Street sees a huge rebound for Viking Therapeutics. Here's why analysts are so optimistic.
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to ...
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after ...
Asianet Newsable on MSN
Can Viking Therapeutics beat big pharma with monthly weight-loss shots? Here’s the risk CEO says could derail it
CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and ...
Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results